Catheter Precision Q1 2024 financials show strong sales, R&D progress, market expansion, and partnerships for cardiac electrophysiology products VIVO & LockeT.
Catheter Precision (NYSE American: VTAK) released Q1 2024 financials and operational report, focusing on innovative products VIVO & LockeT in the growing cardiac electrophysiology market. Q1 highlights: strong sales, continued R&D, market expansion, and solidifying partnerships. Despite challenges, the company remains optimistic about its future growth prospects.
May 06, 2024
3 Articles